Chitosan oligosaccharide enteric-coated dropping pill and application thereof in preparation of medicine for treating non-alcoholic fatty liver disease

A technology of chitosan oligosaccharides and soluble drop pills, which is applied in the field of medicine, can solve the problems of lack of research on the activity and mechanism of chitosan oligosaccharides, easy oxidation and hydrolysis of chitosan oligosaccharides, and poor roundness of enteric-coated dripping pills. To achieve the effects of improving abnormal liver function indicators, enhancing serum antioxidant function, and avoiding oxidation and hydrolysis

Active Publication Date: 2022-04-15
GUANGDONG PHARMA UNIV
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, its main component is not chitosan oligosaccharides, and the research on the activity and mechanism of chitosan oligosaccharides in treating NAFLD is not given. Oxidative hydrolysis by air, reducing the technical problem of treatment effect
[0006] In summary, technical problems such as poor stability of chitosan oligosaccharides and poor roundness of enteric-coated dropping pills generally exist in the prior art.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Chitosan oligosaccharide enteric-coated dropping pill and application thereof in preparation of medicine for treating non-alcoholic fatty liver disease
  • Chitosan oligosaccharide enteric-coated dropping pill and application thereof in preparation of medicine for treating non-alcoholic fatty liver disease
  • Chitosan oligosaccharide enteric-coated dropping pill and application thereof in preparation of medicine for treating non-alcoholic fatty liver disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Embodiment 1, a kind of chitosan oligosaccharide enteric-coated dripping pill and preparation method thereof

[0029] The chitosan oligosaccharide enteric-coated dripping pill is composed of an enteric-coated layer coating and a ball core at a mass ratio of 6:13.

[0030] The enteric layer coating in the chitosan oligosaccharide enteric-coated dropping pills consists of the following components and parts by weight: 20 parts of Eudragit L100-55, 10 parts of talcum powder, 2 parts of polyethylene glycol 6000, ethanol 218 copies.

[0031] The preparation method of the enteric layer coating in the chitosan oligosaccharide enteric-coated dropping pills is as follows: take the Eudragit L100-55 of formula quantity, slowly add to 95 % ethanol, prepared into a suspension with a mass fraction of L100-55 of 8%, and passed through a 80-mesh sieve.

[0032] The core of the oligochitosan enteric-coated dripping pill is composed of the following components and parts by weight thereo...

Embodiment 2

[0035] Embodiment 2, a kind of chitosan oligosaccharide enteric-coated dripping pill and preparation method thereof

[0036] The chitosan oligosaccharide enteric-coated dropping pill is composed of an enteric-coated layer coating and a ball core in a mass ratio of 10:17.

[0037] The enteric layer coating in the chitosan oligosaccharide enteric-coated dropping pills consists of the following components and parts by weight: 40 parts of Eudragit L100-55, 20 parts of talcum powder, 4 parts of polyethylene glycol 6000, ethanol 436 copies.

[0038] The preparation method of the enteric layer coating in the chitosan oligosaccharide enteric-coated dropping pills is as follows: take the Eudragit L100-55 of formula quantity, slowly add to 95 % ethanol, prepared into a suspension with a mass fraction of L100-55 of 8%, passed through an 80-mesh sieve, and obtained.

[0039] The core of the oligochitosan enteric-coated dripping pill is composed of the following components and parts by w...

Embodiment 3

[0042] Embodiment 3, a kind of chitosan oligosaccharide enteric-coated dripping pill and preparation method thereof

[0043] The chitosan oligosaccharide enteric-coated dripping pill is composed of an enteric-coated layer coating and a ball core at a mass ratio of 8:15.

[0044] The enteric layer coating in the chitosan oligosaccharide enteric-coated dropping pills consists of the following components and parts by weight: 31 parts of Eudragit L100-55, 16 parts of talcum powder, 3 parts of polyethylene glycol 6000, ethanol 326 copies.

[0045] The preparation method of the enteric layer coating in the chitosan oligosaccharide enteric-coated dropping pills is as follows: take the Eudragit L100-55 of formula quantity, slowly add to 95 % ethanol, prepared into a suspension with a mass fraction of L100-55 of 8%, passed through an 80-mesh sieve, and obtained.

[0046] The core of the oligochitosan enteric-coated dripping pill is composed of the following components and parts by we...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
Login to view more

Abstract

The invention belongs to the field of medicines, and particularly relates to a chitosan oligosaccharide enteric-coated dropping pill and application thereof in preparation of a medicine for treating non-alcoholic fatty liver disease. The chitosan oligosaccharide enteric-coated dropping pill provided by the invention consists of an enteric-coated layer coating and a pill core in a mass ratio of (6-10): (13-17). The chitosan oligosaccharide enteric-coated dropping pill provided by the invention can improve the hyperglycemia level of an organism and abnormal lipid metabolism caused by high-fat and high-sucrose diet, improve abnormal liver function indexes caused by the high-fat and high-sucrose diet to a certain extent, enhance the serum antioxidant function of a mouse with the non-alcoholic fatty liver disease, promote release of anti-inflammatory factors and improve the anti-inflammatory effect of the mouse with the non-alcoholic fatty liver disease. The purpose of relieving inflammation is achieved, the stability of the chitosan oligosaccharide is enhanced, and the roundness of the chitosan oligosaccharide enteric-coated dropping pill is good.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to a chitosan oligosaccharide enteric-coated dripping pill and its application in the preparation of non-alcoholic fatty liver medicine. Background technique [0002] Non-alcoholic fatty liver disease (NAFLD) is currently the most common chronic liver disease, which further develops into non-alcoholic steatohepatitis (NASH). NAFLD-related complications mainly include hyperlipidemia, obesity, and type II diabetes. NAFLD and NASH The liver-specific mortality and total mortality were 0.77% and 11.77%. The harm of NAFLD to human beings cannot be ignored. Currently, there are few drugs for the treatment of NAFLD in the market, and most of them are still in the experimental stage. There are many application defects and the treatment effect is not good. Therefore, there is an urgent need to develop safe, effective and less side effect drugs for the treatment of NAFLD. [0003] Chitosa...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/32A61K31/722A61K47/32A61K47/10A61K47/02A61P1/16
CPCA61K31/722A61K47/32A61K47/10A61K47/02A61K9/28A61P1/16
Inventor 苏政权白研曹华
Owner GUANGDONG PHARMA UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap